VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2020 | Bispecific antibodies for non-Hodgkin lymphoma

Martin Hutchings, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, reflects on the use of bispecific antibodies in the treatment of non-Hodgkins lymphoma, including glofitamab and epcoritamab, both CD20xCD3 bispecific antibodies. Furthermore, Dr Hutchings elaborates on the implementation of bispecific antibodies in the treatment regime of non-Hodgkins lymphoma patients and its curative potential for highly refractory patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter